Soluble Biomarkers for Neuromyelitis Optica Spectrum Disorders: a Mini Review

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 May 31

PMID 38817544

Authors

Rachel E Rodin

Tanuja Chitnis

Affiliations

Soon will be listed here.

Abstract

The Neuromyelitis Optica Spectrum Disorders (NMOSD) constitute a spectrum of rare autoimmune diseases of the central nervous system characterized by episodes of transverse myelitis, optic neuritis, and other demyelinating attacks. Previously thought to be a subtype of multiple sclerosis, NMOSD is now known to be a distinct disease with unique pathophysiology, clinical course, and treatment options. Although there have been significant recent advances in the diagnosis and treatment of NMOSD, the field still lacks clinically validated biomarkers that can be used to stratify disease severity, monitor disease activity, and inform treatment decisions. Here we review many emerging NMOSD biomarkers including markers of cellular damage, neutrophil-to-lymphocyte ratio, complement, and cytokines, with a focus on how each biomarker can potentially be used for initial diagnosis, relapse surveillance, disability prediction, and treatment monitoring.

Citing Articles

Transcriptome signature in the blood of neuromyelitis optica spectrum disorder under steroid tapering.

Yamamura R, Kinoshita M, Yasumizu Y, Yata T, Kihara K, Motooka D Front Immunol. 2025; 16:1508977.

PMID: 39963140 PMC: 11830620. DOI: 10.3389/fimmu.2025.1508977.

Blood-Brain Barrier Disruption in Neuroimmunological Disease.

Shimizu F, Nakamori M Int J Mol Sci. 2024; 25(19).

PMID: 39408955 PMC: 11476930. DOI: 10.3390/ijms251910625.

Humanized-Aquaporin-4-Expressing Rat Created by Gene-Editing Technology and Its Use to Clarify the Pathology of Neuromyelitis Optica Spectrum Disorder.

Namatame C, Abe Y, Miyasaka Y, Takai Y, Matsumoto Y, Takahashi T Int J Mol Sci. 2024; 25(15).

PMID: 39125739 PMC: 11311328. DOI: 10.3390/ijms25158169.

References

Hofer L, Mariotto S, Wurth S, Ferrari S, Mancinelli C, Delogu R . Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Mult Scler J Exp Transl Clin. 2019; 5(2):2055217319848463. PMC: 6537078. DOI: 10.1177/2055217319848463. View

Wang H, Wang K, Wang C, Qiu W, Lu Z, Hu X . Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand J Immunol. 2013; 79(2):127-30. DOI: 10.1111/sji.12132. View

Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S . Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010; 16(12):1443-52. DOI: 10.1177/1352458510379247. View

Chen B, Gui M, Ji S, Xie Y, Tian D, Bu B . Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System. Neuroimmunomodulation. 2021; 29(3):220-230. DOI: 10.1159/000519835. View

Liu C, Lu Y, Wang J, Chang Y, Wang Y, Chen C . Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. J Neurochem. 2021; 159(5):913-922. DOI: 10.1111/jnc.15478. View

Pache F, Ringelstein M, Aktas O, Kleiter I, Jarius S, Siebert N . C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. J Neuroimmunol. 2021; 360:577699. DOI: 10.1016/j.jneuroim.2021.577699. View

Zhang T, Chen J, Du C, Zeng P, Zhang H, Wang X . Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord. 2021; 14:17562864211054952. PMC: 8573482. DOI: 10.1177/17562864211054952. View

Tuzun E, Kurtuncu M, Turkoglu R, Icoz S, Pehlivan M, Birisik O . Enhanced complement consumption in neuromyelitis optica and Behçet's disease patients. J Neuroimmunol. 2011; 233(1-2):211-5. DOI: 10.1016/j.jneuroim.2010.11.010. View

Aktas O, Hartung H, Smith M, Rees W, Fujihara K, Paul F . Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023; 94(9):757-768. PMC: 10447388. DOI: 10.1136/jnnp-2022-330412. View

10.

Chang X, Huang W, Wang L, ZhangBao J, Zhou L, Lu C . Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Front Immunol. 2021; 12:647618. PMC: 8008082. DOI: 10.3389/fimmu.2021.647618. View

11.

Shi Z, Du Q, Wang X, Wang J, Chen H, Lang Y . Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders. Front Immunol. 2022; 13:1027158. PMC: 9682179. DOI: 10.3389/fimmu.2022.1027158. View

12.

Manin A, Justo M, Leoni J, Paz M, Villa A . C5a complement levels in clinical remission AQP4-IgG-positive NMO patients. Acta Neurol Belg. 2023; 123(4):1447-1451. DOI: 10.1007/s13760-023-02261-7. View

13.

Pittock S, Berthele A, Fujihara K, Kim H, Levy M, Palace J . Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7):614-625. DOI: 10.1056/NEJMoa1900866. View

14.

Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, Misu T . Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol. 2012; 254(1-2):178-82. DOI: 10.1016/j.jneuroim.2012.09.002. View

15.

Zhong X, Wang H, Dai Y, Wu A, Bao J, Xu W . Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2011; 240-241:104-8. DOI: 10.1016/j.jneuroim.2011.10.001. View

16.

Cabanillas-Lazo M, Cruzalegui-Bazan C, Pascual-Guevara M, Quispe-Vicuna C, Terry-Escalante F, Mori N . Clinical and imagenologic significance of the neutrophil-to-lymphocyte ratio in neuromyelitis optica spectrum disorder: A systematic review with meta-analysis. PLoS One. 2023; 18(2):e0281064. PMC: 9910629. DOI: 10.1371/journal.pone.0281064. View

17.

Kim H, Lee E, Kim S, Choi L, Kim H, Kim H . Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler. 2021; 28(4):512-521. DOI: 10.1177/13524585211024978. View

18.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D . Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019; 93(13):e1299-e1311. DOI: 10.1212/WNL.0000000000008160. View

19.

Qin C, Chen B, Tao R, Chen M, Ma X, Shang K . The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019; 35:1-4. DOI: 10.1016/j.msard.2019.06.035. View

20.

Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y . Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010; 75(3):208-16. DOI: 10.1212/WNL.0b013e3181e2414b. View